RenovoRx (Nasdaq: RNXT) is bolstering its intellectual property (IP) portfolio with a new international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, adding to its existing 18 issued and 13 pending patents. The new application details methods and tools for targeted drug delivery using micro-vessels surrounding larger arteries, aiming to improve treatment efficacy and reduce systemic toxicity associated with intravenous delivery. The company is concurrently advancing commercial plans for its FDA-cleared RenovoCath delivery system and its Phase III TIGeR-PaC clinical trial, both leveraging the TAMP platform.
This targeted drug delivery technology has the potential to reshape cancer treatment. Direct delivery to tumor sites via the vasa vasorum offers a more precise and potentially less toxic alternative to traditional intravenous chemotherapy, addressing a critical need for improved treatment options with fewer side effects. Specifically, for pancreatic cancer, a notoriously difficult-to-treat disease, the TAMP approach could represent a significant advancement in patient care.
RenovoRx’s expanded IP protection for TAMP is crucial for securing its market position and maximizing the platform’s value. The company is pursuing commercialization of RenovoCath as a standalone device and anticipates completing enrollment and a second interim analysis for its TIGeR-PaC trial, which is evaluating gemcitabine delivered via TAMP for locally advanced pancreatic cancer, in the first half of 2025. Furthermore, the company has recently received its first purchase orders for RenovoCath, indicating initial market traction.
The combination of progressing clinical trials, growing IP protection, and initial commercial orders suggests a positive trajectory for RenovoRx. A successful outcome in the TIGeR-PaC trial combined with robust IP could position RenovoRx as a leader in targeted cancer therapy, significantly impacting the oncology landscape. This focused approach to drug delivery could lead to broader adoption of TAMP-powered treatments, offering patients a more effective and tolerable option for combating various cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
